Molecular diagnostics firm Great Basin Scientific has appointed Jeffrey Rona as CFO. His appointment went into effect on Oct. 8 in conjunction with the company's initial public offering.
Rona has served as a financial consultant to Great Basin since 2012 in his role as the managing director of Rona Capital, a life sciences-focused transactional advisory consultancy founded in 2011. From 2006 to 2011, Rona was the chief business officer of GlobeImmune. Prior to that, he was vice president of corporate development for Corgentech, following the merger between Corgentech and AlgoRx Pharmaceuticals in 2005. At AlgoRx, he was CFO and responsible for the execution of the merger with Corgentech. Rona has also worked for UBS Warburg, Antigenics (now Agenus), and Coopers and Lybrand.